Mitochondrial dysfunction is associated with neuronal damage in Huntington's disease (HD), but the precise mechanism of mitochondria-dependent pathogenesis is not understood yet. Herein, we found that colocalization of XIAP and p53 was prominent in the cytosolic compartments of normal subjects but reduced in HD patients and HD transgenic animal models. Overexpression of mutant Huntingtin (mHTT) reduced XIAP levels and elevated mitochondrial localization of p53 in striatal cells in vitro and in vivo. Interestingly, XIAP interacted directly with the C-terminal domain of p53 and decreased its stability via autophagy. Overexpression of XIAP prevented mitochondrially targeted-p53 (Mito-p53)-induced mitochondrial oxidative stress and striatal cell death, whereas, knockdown of XIAP exacerbated Mito-p53-induced neuronal damage in vitro. In vivo transduction of AAV-shRNA XIAP in the dorsal striatum induced rapid onset of disease and reduced the lifespan of HD transgenic (N171-82Q) mice compared to WT littermate mice. XIAP dysfunction led to ultrastructural changes of the mitochondrial cristae and nucleus morphology in striatal cells. Knockdown of XIAP exacerbated neuropathology and motor dysfunctions in N171-82Q mice. In contrast, XIAP overexpression improved neuropathology and motor behaviors in both AAV-mHTT-transduced mice and N171-82Q mice. Our data provides a molecular and pathological mechanism that deregulation of XIAP triggers mitochondria dysfunction and other neuropathological processes via the neurotoxic effect of p53 in HD. Together, the XIAP-p53 pathway is a novel pathological marker and can be a therapeutic target for improving the symptoms in HD.
1 January 1999 in Alzheimer Disease & Associated Disorders
The molecular bases of Alzheimer disease and related neurodegenerative disorders are becoming better understood, but the means for definitive diagnosis and monitoring in vivo remain lacking. Near-infrared optical spectroscopy offers a potential solution. We acquired transmission and reflectance spectra of thin brain tissue slabs, from which we calculated wavelength-dependent absorption and reduced scattering coefficients from . The reduced scattering coefficients in the near infrared clearly differentiated Alzheimer from control specimens. Diffuse reflectance spectra of gross brain tissue in vitro confirmed this observation. These results suggest a means for diagnosing and monitoring Alzheimer disease in vivo, using near-infrared optical spectroscopy.
BCBoston University Alzheimer’s Disease Research Center
Boston University Alzheimer’s Disease Research Center
+11
Background: Identification of blood‐based biomarkers that are indicative of Alzheimer’s disease (AD) pathology may help with early detection.Methods: We generated proteome data for ∼7,000 proteins in both antemortem plasma and postmortem brain tissue from 103 participants of the Boston University Alzheimer’s Disease Research Center. All participants completed comprehensive neuropsychological evaluations and dementia severity was measured by global cognitive dementia rating (CDR) scores. A pathological AD diagnosis was established using NIA Reagan criteria. We conducted association tests with dementia (i.e., CDR ≥1 for dementia, CDR <1 for control) and autopsy‐confirmed AD status as binary outcomes. Plasma proteins significantly associated with clinical or pathological AD (P<0.05) were tested for association with quantitative cognitive tests and AD‐related neuropathological traits in which outcomes were rank‐transformed after adjusting for sex and either age at last antemortem exam or death.Results: Of the 103 brain donors, 43 were diagnosed with dementia and 55 had autopsy‐confirmed AD. Five proteins (ACES, AURKB, CBARP, G45IP, and MMP‐8) measured in plasma were significantly associated with both pathological AD and dementia, while 252 plasma proteins were associated with either diagnosis (P<0.05). MMP‐8 was the only protein that was significantly associated in both plasma and brain with autopsy‐confirmed AD (Pplasma = 0.005, Pbrain = 0.001) and dementia (Pplasma = 0.01, Pbrain = 9×10−5). ACES and AURKB levels in plasma and brain were significantly associated with dementia (P<0.05). Levels of these. Increased MMP‐8 level in plasma was associated with decreased animals (P = 0.03) and scores (P = 0.04), which both assess verbal fluency. Dementia and pathologically confirmed AD were associated with lower AURKB and elevated ACES levels in plasma. Decreased plasma ACES level was associated with executive function (TrailsB: P = 0.01) and language (Boston Naming Test: P = 0.02) impairment, and the reduced plasma AURKB level was associated with memory impairment (Logical Memory Immediate Recall score: P = 0.03).Conclusion: MMP‐8, a neutrophil collagenase and member of the matrix metalloproteinase family, is a potential blood‐based biomarker for dementia and underlying AD pathology and is associated predominantly with impaired verbal fluency.
We previously reported that 50% of cognitively intact elderly have dense neurofibrillary degeneration in Brodmann area (BA) 19/37. We now report the finding of focal tau pathology in the posterior cortex of a cognitively intact identical twin at high risk for AD. A male Caucasian chemical engineer developed AD symptoms at age 60, first manifest as the inability to read maps, followed by progressive loss of memory and intellect over 16 years until his death at age 76. Post‐mortem exam confirmed severe AD (NIA‐Reagan: high, CERAD plaque: frequent, Braak: VI). His identical twin, also a chemical engineer with an identical education, died at 79 years from prostate cancer. At the time of his death, he was cognitively intact, except for slight loss of his navigational skills. Post‐mortem exam revealed sparse neuritic plaques and entorhinal and transentorhinal NFTs (NIA‐Reagan: low, CERAD: sparse, Braak: II). Despite the mild non‐diagnostic AD changes, there were dense NFTs, neuropil threads and tau immunoreactive neuritic plaques in the posterior cortex, BA 19/37. The finding of dense BA 19/37 pathology in this monozygotic twin, at high risk for the development of AD, but in the preclinical stages of AD at the time of his death, further confirms the early neurofibrillary degeneration of the posterior cortex in some individuals prior to the development of AD. Supported by NIA P30 AG13846, and by the Dept of Veteran's Affairs.